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CLINICAL RESEARCH
Sudden death and ICDs
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Aims Comorbidity burden has been linked to survival in patients with an implantable cardioverter-defibrillator (ICD), but
no study has examined the influence on psychological well-being and health status. We examined the relationship
between comorbidity burden and anxiety, depression, and health status in patients with an ICD during the first
12 months post-implantation using a prospective study design.
Methods
and results
Consecutively, implanted ICD patients (N ¼ 401; 78% men) completed the Hospital Anxiety and Depression Scale
and the Short Form Health Survey 36 (SF-36) at baseline, 3, 6, and 12 months post-implantation. Data were analysed
using general linear mixed modelling repeated measures multivariable analysis of variance. The mean Charlson co-
morbidity index score was 3.5 (+2.4). In adjusted analyses, comorbidity burden was significantly associated with de-
pression (P ¼ 0.003) and the physical health status domains of the SF-36 (Physical Functioning: P , 0.001; Role
Limitations—Physical: P ¼ 0.023; Bodily Pain: P ¼ 0.004; and General Health: P ¼ 0.025) but not with anxiety
(P ¼ 0.62) and the mental health status domains of the SF-36 (all P’s . 0.05). Chronic heart failure, chronic obstruct-
ive pulmonary disease, cerebrovascular disease, and renal failure were the comorbidities with the most impact on
depression and physical health status.
Conclusion Comorbidity burden was a significant predictor of poorer psychological well-being and physical health status in ICD
patients during the first 12 months post-implantation. In the care and management of ICD patients, it is important to
recognize the impact of comorbidity burden on patients’ mood and health status, and that adjunctive intervention
may be warranted to enhance well-being.
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Introduction
The implantable cardioverter-defibrillator (ICD) is the first-choice
therapy for patients at risk for sudden cardiac death due to ven-
tricular arrhythmias.1,2 Despite the effectiveness of ICD therapy
demonstrated in clinical trials, patients enrolled in clinical trials
do not fully reflect ICD patients seen in the real-world clinical
setting, due to the former being younger and having less
comorbidities.3
The presence of multiple comorbid conditions is associated with
a poorer survival.4 –6 As a result of poorer physical functioning and
increased problems in daily life, a higher number of comorbidities
may also influence patients’ psychological well-being, including
symptoms of anxiety and depression, and health status.6– 8
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Monitoring psychological status of patients with multiple co-
morbidities is thus of utmost importance, in particular because
the variability in clinical presentation and types of comorbidities
present may hinder the detection of psychological distress.9 To
our knowledge, no previous study has examined the impact of co-
morbidities on the well-being and health status of ICD patients but
rather tend to have focused on the impact of ICD therapy. In add-
ition, as the population of ICD patients is very heterogeneous with
patients receiving implantation for a wide range of indications, the
risk of an increased comorbidity burden is high.
The purpose of the current study was to examine the associ-
ation between patients’ pre-implantation Charlson comorbidity
index (CCI) score, and anxiety, depression, and health status in
patients with an ICD during the first 12 months post-implantation
using a prospective study design.
Methods
Patients and study design
Between August 2003 and February 2010, 448 consecutive patients
who were implanted with a first-time ICD in the Erasmus Medical
Center, Rotterdam, The Netherlands, were enrolled in the Mood
and personality as precipitants of arrhythmia in patients with an
Implantable cardioverter Defibrillator: A prospective Study (MIDAS).
Patients with a life-expectancy of ,1 year, being on the waiting list
for heart transplantation, a history of psychiatric illness other than af-
fective/anxiety disorders, or insufficient knowledge of the Dutch lan-
guage, were excluded.
The study protocol was approved by the Medical Ethics Committee
of the Erasmus Medical Center, and the study was conducted accord-
ing to the Helsinki Declaration. An ICD nurse provided written and
oral information on the study prior to ICD implantation. After obtain-
ing written informed consent, patients were asked to complete a set of
standardized and validated questionnaires at baseline (i.e. 1 day prior
to implantation), and at 3, 6, and 12 months post-implantation. Infor-
mation on baseline demographics and clinical characteristics was
extracted from patients’ medical records and purpose-designed ques-
tions in the questionnaires.
Measures
Comorbidities and the Charlson comorbidity index
Information on comorbidities prior to ICD implantation was obtained
via chart abstraction from the patients’ medical records and laboratory
values at baseline. Renal functioning was assessed by estimating the
baseline glomerular filtration rate (eGFR), according to the abbreviated
Modification of Diet in Renal Disease (MDRD) Study equation.10 In ac-
cordance with practice guidelines, an eGFR ,60 mL/min/1.73 m2 was
considered as impaired renal functioning.11 An abbreviated CCI score
was composed with the following comorbid conditions: myocardial in-
farction (MI), congestive heart failure, cerebrovascular disease, chronic
obstructive pulmonary disease, diabetes mellitus, peripheral vascular
disease, renal failure, and any malignancy excluding metastatic
tumours.5 In order to obtain a comorbidity index that is in accordance
with the original CCI, a weight of 2 was assigned to renal failure and
any malignancy, and a weight of 1 to the other comorbid conditions.12
By adding up the values assigned to each comorbid condition, a co-
morbidity score was calculated for each patient. Because age is a risk
factor for mortality independent of the presence of comorbid condi-
tions and the incidence of comorbidities increased with higher age in
our sample, we adjusted the score by adding one point to the score
for each decade of life over the age of 50 years at the time of study
entry, according to the validated combined comorbidity index.5,13
The advantage of this abbreviated index is that it reckons with the co-
morbid disorders most prevalent in and relevant to cardiac patients,
and that age is included as an additional indicator of health.
Psychological well-being and health status
Symptoms of anxiety and depression were measured at baseline, and
at 3, 6, and 12 months follow-up using the Hospital Anxiety and De-
pression Scale (HADS).14 The HADS consists of seven items measur-
ing symptoms of anxiety (HADS-A) and seven items measuring
symptoms of depression (HADS-D), all scored on a 4-point Likert
scale.14 Scores range from 0 to 3 (total score range of 0–21), with
higher scores reflecting more symptoms.14 The HADS has good psy-
chometric properties.15
The Short Form Health Survey 36 (SF-36) was used to assess
patients’ health status at baseline, and at 3, 6, and 12 months post-
implantation.16 The items contribute to eight subscales: Physical func-
tioning, Role Limitations—Physical, Bodily Pain, Social Functioning,
Mental Health, Role Limitations—Emotional, Vitality and General
Health. Scores on the individual subscales range from 0 to 100, with
higher scores indicating better health status, and a higher score on
the Bodily Pain subscale indicating the absence of pain.17 Psychometric
properties for the SF-36 are adequate.16
Type D personality is the combined tendency to experience
increased negative affectivity and social inhibition. The 14-item Type
D scale (DS14), consisting of seven items measuring negative affectivity
(i.e. ‘I often feel unhappy’) and seven items measuring social inhibition
(i.e. ‘I am a closed kind of person’), was used to assess Type D person-
ality at baseline.18 All items are scored on a 5-point Likert scale,
ranging from 0 (false) to 4 (true), with a total score ranging from 0
to 28.18 A cut-off score of ≥10 on both subscales defines individuals
with a Type D personality.19
Statistical analyses
Repeated measures multivariable analysis of variance using general
linear mixed modelling analysis was performed to test the longitudinal
association between CCI and psychological well-being. This technique
uses the data efficiently by also including incomplete cases in analyses.
What’s new?
† The impact of comorbidities on psychological well-being and
health status in patients with an implantable cardioverter-
defibrillator (ICD) has not yet been investigated, as the
main focus has previously been the impact of the ICD
itself in relation to psychological well-being.
† Implantable cardioverter-defibrillator patients comprise a
heterogeneous group at increased risk of having multiple co-
morbid conditions. As a result of heterogeneous presenta-
tion, detection of psychological distress is more difficult
and these patients are at increased risk of not receiving
the psychological care they need.
† The use of general linear mixed modelling analysis, a power-
ful statistical technique to analyse the data, reducing non-
response bias and increasing statistical power.
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As a result of this, bias is limited and statistical power is preserved.
First, intra-class correlations, a measure of score dependencies
within patients, were computed for anxiety, depression and each of
the SF-36 subscales. First, the CCI was tested as an associate of psy-
chological well-being and health status over time; secondly, we
assessed which individual comorbidities mainly accounted for the asso-
ciation between CCI and psychological well-being and health status.
A priori, we adjusted for gender, educational level, indication for
ICD therapy, the presence of cardiac resynchronization therapy
(CRT), ICD shocks, atrial fibrillation, smoking, the use of amiodarone,
beta-blockers, and diuretics, the presence of psychological treatment,
and Type D personality in multivariable analyses. All independent vari-
ables were defined as fixed variables (i.e. not varying over time). Ana-
lyses were performed using PASW Statistics 19 statistical software
(PASW IBM Corp). For all tests, a P , 0.05 was considered to be stat-
istically significant. The described effects in the ‘Results’ section are the
relationship of CCI at any time point with the level of anxiety and de-




Of the 448 patients, 18 had missing data on one or more psycho-
logical measures. Twenty-nine patients had additional missing data
on one or more clinical baseline characteristics. No systematic dif-
ferences were found between patients included (n ¼ 401) and
patients excluded (n ¼ 47) from analyses (all P . 0.05). The popu-
lation was predominantly male (78%), with a mean age of 58+ 12
years. Baseline characteristics of the study population are pre-
sented in Table 1. The prevalence of comorbid conditions included
in the CCI is displayed in Figure 1. The most common non-cardiac
comorbid conditions were renal failure, diabetes mellitus, and
cerebrovascular disease. The number of comorbid conditions in
patients varied from 0 to 6, with 25% of the patients having ≥3 co-
morbid conditions. Nineteen per cent of the patients had ≥2 non-
cardiac comorbidities. Charlson comorbidity index scores ranged
from 0 to 10, with the mean CCI score being 3.5+ 2.4. In the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .




Mean age (+SD) 58.4 (12.2)
Men 314 (78.3)
Single/no partner 26 (6.5)
Low educationb 231 (57.6)
Clinical risk factors
Primary prevention indication 265 (66.1)
CRT 112 (27.9)
Shocks during follow-upc 58 (14.5)
LVEF ≤35%d 300 (74.8)
Mean QRS (ms) (+SD) 130.3 (36.2)
CAD 231 (57.6)
Previous PCI 105 (26.2)
Previous CABG 83 (20.7)






ACE inhibitors 288 (71.8)
Statins 237 (59.1)
Digoxin 63 (15.7)
Psychological treatmente 77 (19.2)
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft surgery;
CAD, coronary artery disease; CRT, cardiac resynchronization therapy; LVEF, left
ventricular ejection fraction; MI, myocardial infarction; N, number; PCI,
percutaneous coronary intervention; QRS, QRS duration; SD, standard deviation.
aResults are presented as N (%), unless otherwise indicated.
bEducation ≤13 years.
cBoth appropriate (N ¼ 44; 11.0%) and inappropriate (N ¼ 16; 4.0%) shocks.
dFifty-three of 401 (13.2% missing).
eBoth psychotropic medication and treatment by a psychologist.
Figure 1 Prevalence (%) of the different comorbid conditions in the total study population. *Excluding metastatic tumours. CHF, chronic
heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PAD, peripheral arterial disease.
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12 months period post-implantation, 15% of the patients received
a shock, of which 4% was inappropriate.
Charlson comorbidity index as a
determinant of psychological well-being
and health status
Figure 2 depicts mean scores for anxiety, depression, and health
status during the 12-month follow-up period. First, intra-class cor-
relations were computed as a measure of correlation between the
different measurement occasions (i.e. baseline, 3, 6, and 12 months
follow-up). The consecutive measurements of anxiety and depres-
sion both showed an intra-class correlation of 0.30. With regard to
health status, intra-class correlations varied from 0.37 to 0.73 for
Role Limitations—Emotional and General Health, respectively, in-
dicating a moderate to high correlation between the measurement
moments, supporting the use of this specific repeated measures
technique.
In Table 2, the results of the mixed modelling analyses are
expressed as estimates, 95% confidence intervals (CIs), t- and
P-values. A higher CCI prior to implantation was associated with
more symptoms of depression over the follow-up period (P ¼
0.003). No association was found between CCI and anxiety. In
multivariable analyses, the CCI remained as a significant predictor
of depressive symptoms at any time point (P ¼ 0.003) (Table 2).
With respect to the health status, in univariable analyses, a
higher CCI prior to implantation was associated with poorer phys-
ical health status over the follow-up period, in terms of Physical
Functioning (P , 0.001), Role Limitations—Physical (P , 0.001),
more Bodily Pain (P ¼ 0.002), poorer Role Limitations—Emotional
(P ¼ 0.026), Vitality (P ¼ 0.010), and General Health (P , 0.001).
In multivariable analyses, the association between CCI and health
status remained significant for Physical Functioning (P , 0.001),
Role Limitations—Physical (P ¼ 0.023), Bodily Pain (P ¼ 0.004),
and General Health (P ¼ 0.025) (Table 2).
The individual components of the
Charlson comorbidity index as
determinants of psychological well-being
and health status
Subsequently, we investigated whether specific comorbidities
included in the CCI accounted for the significant effects on psycho-
logical well-being and health status as displayed in Table 2. Chronic
heart failure, chronic obstructive pulmonary disease, cerebrovascu-
lar disease, and renal failure were the most important predictors of
depression and impaired health status (for all subscales, shown in
Table 3). No individual effect of the different comorbidities was
found on symptoms of anxiety. In multivariable analyses, when all
comorbidities were entered in the model simultaneously, chronic
heart failure, chronic obstructive pulmonary disease, cerebrovascu-
lar disease, and renal failure remained the most important predic-
tors. Additionally, although age alone did not strongly predict
psychological well-being and health status, it was an important de-
terminant when all comorbidities were combined into one model.
Discussion
To our knowledge, this is the first study in ICD patients to
examine the influence of comorbidity burden on psychological
well-being and health status. We found that patient’s comorbidity
burden was an important predictor of psychological well-being
and health status over the 12 months post-implantation. Having
a higher comorbidity burden was associated with more symptoms
of depression, but not anxiety, and with poorer physical function-
ing, more physical role limitations, more bodily pain and a poorer
general health. Importantly, this association was present inde-
pendent of the patient’s pre-implantation personality profile,
which has also shown to be an important predictor of anxiety, de-
pression, and health status in patients with an ICD.20 Our results
Figure 2 Mean scores of anxiety, depression, and health status
during the 12 months post-implantation.
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correspond in part to findings of previous studies in the general
older population6,7 and in patients with acute MI,8 where a
higher comorbidity burden was found to be associated with
more depressive symptoms and functional impairment. In patients
with CRT, who also comprise an important group in our sample,
the relationship between comorbidities and psychological well-
being has not been investigated yet. However, as the course of
health status in patients with CRT is comparable with the
course of health status found in our study,21,22 we expect that
patients with CRT show a similar association between comorbid-
ity burden and psychological well-being as patients with a defibril-
lator only.
We found no association between comorbidity score and
anxiety. Around 25% of ICD patients report increased levels of
anxiety.20,23 However, the type of impairments in patients with
multiple comorbidities might more easily induce symptoms of de-
pression, by interfering with the patient’s physical activity level,
sleeping pattern, and social relationships, which in turn may lead
to feelings of hopelessness and guilt.6,8 This pattern corresponds
more with depressive rather than anxious symptomatology.
No association was found between CCI score and mental health
status. One would probably expect that in case of a positive asso-
ciation between CCI score and depressive symptoms, an associ-
ation between CCI score and mental health status would also be
present. However, the mental health status subscales of the
SF-36, as used in the current study, may be too generally formu-
lated and do not measure specific psychological problems, includ-
ing symptoms of anxiety and depression. In addition, the mental
health subscale has shown to lack sensitivity to measure changes
in mental health.24
Chronic heart failure, chronic obstructive pulmonary disease,
cerebrovascular disease, and renal failure were the most important
associates of depressive symptoms and poorer health status. These
comorbidities have both a worse short-term and long-term prog-
nosis when compared with the other comorbidities. In addition,
these patients may experience more restrictions both in physical
and mental functioning. Their adverse impact on psychological
well-being and health status is illustrated in our study. Cancer
did not seem to have an influence on health status and symptoms
of anxiety and depression in our patient group. However, as
patients were asked to report on lifetime presence of cancer, a
time span between the actual presence of cancer and the assess-
ment of psychological problems could account for the absence
of the relationship.
The finding that comorbid conditions are associated with
poorer well-being and impaired health status is important for clin-
ical practice. The variability in clinical presentation makes it difficult
for physicians to detect psychological distress.9 Physicians might at-
tribute patients’ psychological symptoms to their comorbidities
rather than to psychological difficulties. However, it remains an im-
portant issue to focus on in daily practice, as both health status and
depression have shown to be independent predictors of health
care utilization in heart failure patients.25,26 In addition, previous
studies have shown that patients with comorbidities respond
less well to psychological therapy than patients without such
comorbidities.27,28
The limitations of this study should be acknowledged. First, it
would have been interesting to investigate whether changes in
CCI scores over time were predictive of psychological status
during follow-up. However, information on comorbidities was
only available at baseline. In addition, information on psychological
well-being was based on self-report measures instead of clinical
diagnoses according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR).
However, minor depressive symptoms have also been associated
with functional decline and mortality in cardiac patients.29,30
Finally, the relatively short follow-up period does not allow
drawing conclusions on the long-term relationship between CCI
scores and psychological status.
This study also has important strengths. Research on the rela-
tionship between comorbid conditions and psychological function-
ing has mainly been focusing on symptoms of depression, while the
influence on symptoms of anxiety and general daily functioning has
been largely ignored. Furthermore, we used a powerful statistical
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Charlson comorbidity index as a determinant of anxiety, depression, and health status (adjusted analysis)a
Estimate 95% CI t P
Anxiety 20.06 [20.19 to 0.08] 20.84 0.40
Depression 0.21 [0.07 to 0.35] 2.95 0.003
SF-36 subscales
Physical Functioning 22.57 [23.57 to 21.58] 25.08 ,0.001
Role Limitations—Physical 21.67 [23.10 to 20.23] 22.29 0.023
Bodily Pain 21.31 [22.19 to 20.43] 22.92 0.004
Social Functioning 20.36 [21.20 to 0.49] 20.83 0.41
Mental Health 20.19 [20.80 to 0.43] 20.60 0.55
Role Limitations— Emotional 21.05 [22.32 to 0.22] 21.62 0.11
Vitality 20.64 [21.41 to 0.13] 21.64 0.10
General Health 20.97 [21.82 to 20.12] 22.25 0.025
aAdjusted for gender, educational level, indication for ICD therapy, CRT, the occurrence of shocks (both appropriate and inappropriate) during the 12 months post-implantation,
atrial fibrillation, smoking, the use of amiodarone, beta-blockers, and diuretics, the presence of psychological treatment, and Type D personality.
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Table 3 Individual comorbidities from the Charlson comorbidity index as predictors of psychological well-being and health status
Psychological
measures





HADS e P e P e P e P e P e P e P e P e P
Anxiety 20.32 0.06* 0.05 0.89 0.14 0.68 0.02 0.95 0.49 0.32 20.40 0.55 0.87 0.12 1.18 0.08 20.62 0.33
Depression 0.23 0.20 1.09 0.006 0.51 0.15 0.79 0.030 0.58 0.25 1.10 0.11 1.09 0.06 1.52 0.026 20.21 0.75
SF-36
PF 22.76 0.016 212.32 ,0.001* 22.69 0.25 214.03 ,0.001‡ 29.49 0.004 27.95 0.08 213.25 ,0.001† 221.13 ,0.001‡ 25.38 0.21
RL-P 22.78 0.08 29.65 0.009 21.18 0.72 215.93 ,0.001‡ 29.40 0.044 24.52 0.47 210.19 0.06 220.93 0.001* 24.28 0.48
BP 21.76 0.07 22.97 0.19 22.58 0.20 24.94 0.015 27.81 0.006* 211.0 0.004* 29.76 0.003* 27.45 0.049 20.33 0.93
SF 0.99 0.32* 23.89 0.09 21.62 0.42 27.44 ,0.001† 25.20 0.07 24.72 0.22 27.09 0.031 213.95 ,0.001† 2.60 0.48
MH 0.95 0.22* 22.20 0.21 21.30 0.41 21.70 0.29 21.98 0.38 23.19 0.29 23.95 0.12 26.40 0.033 2.82 0.33
RL-E 21.71 0.25 26.31 0.06 27.84 0.008* 23.67 0.23 27.27 0.09 20.71 0.90 26.39 0.19 25.60 0.33 5.88 0.28
VT 0.36 0.69 25.66 0.006 1.20 0.52 28.51 ,0.001† 22.22 0.40 24.74 0.18 27.50 0.012* 29.81 0.005* 20.49 0.89
GH 0.15 0.88* 28.90 ,0.001* 22.15 0.28 212.59 ,0.001‡ 26.76 0.016 24.30 0.26 27.92 0.012 211.78 0.002* 22.09 0.57
BP, Bodily Pain; CHF, chronic heart failure; CVA, cerebrovascular accident; DM, diabetes mellitus; e, estimate; GH, General Health; MH, Mental Health; MI, myocardial infarction; PAD, peripheral arterial disease; PF, Physical Functioning; PROs,
patient-reported outcomes; RL-E, Role Limitations—Emotional; RL-P, Role Limitations—Physical; SF, Social Functioning; SF-36, Short Form Health Survey 36; TIA, transient ischaemic attack; VT, Vitality.
*Significant on a P , 0.05 level in multivariable analyses (all comorbidities together in one model).
†Significant on a P , 0.01 level in multivariable analyses.
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technique to analyse the data, reducing non-response bias and in-
creasing statistical power.
In conclusion, we found that patients with a higher comorbidity
score reported more symptoms of depression and poorer health
status on several domains. As the variability in clinical presentation
of patients with comorbid conditions may hinder physicians from
detecting psychological distress and referring the patient to ad-
equate, tailor-made psychological care, in case of comorbidities, clin-
icians should be vigilant of the possibility that patients’ psychological
well-being and health status is at higher risk of being affected.
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